Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Prajwal Boddu, Hagop Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Michael Andreeff, Elias J. Jabbour, Christopher B. Benton, Courtney D. DiNardo, Marina Konopleva, Naval Daver, Keyur Patel, Koichi Takahashi, Rashmi Kanagal-Shamanna, Jorge Cortes & Tapan Kadia. (2018) Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leukemia & Lymphoma 59:9, pages 2238-2241.
Read now
Read now
Michael E. Williams, Joseph M. Connors, Martin H. Dreyling, Randy D. Gascoyne, Brad S. Kahl, John P. Leonard, Oliver W. Press & Wyndham H. Wilson. (2011) Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukemia & Lymphoma 52:1, pages 24-33.
Read now
Read now
Jeffrey L Bennett & Augusto A Miravalle. (2010) Recent advances in the treatment of multiple sclerosis. Journal of Experimental Pharmacology 2, pages 155-161.
Read now
Read now
John R Corboy & Augusto A Miravalle. (2010) Emerging therapies for treatment of multiple sclerosis. Journal of Inflammation Research 3, pages 53-59.
Read now
Read now
Patricia Hentosh & Dennis M Peffley. (2010) The cladribine conundrum: deciphering the drug's mechanism of action. Expert Opinion on Drug Metabolism & Toxicology 6:1, pages 75-81.
Read now
Read now
Articles from other publishers (42)
Komal Singh. 2024. Encyclopedia of Toxicology. Encyclopedia of Toxicology
319
327
.
Xinhong Fei, Weijie Zhang, Jiangying Gu, Fan Yang, Tingting Li, Wenjing Wang & Jingbo Wang. (2023) CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Annals of Hematology.
Crossref
Crossref
Dan-Xia Ying, Peng-Cheng Zhao, Wen Zhang & Guo-Wu Rao. (2023) Research Progress in Competitive Purine Antagonists. Current Medicinal Chemistry 30:34, pages 3880-3904.
Crossref
Crossref
Guillermo Cruz, Laura Pilar Saiz, Muhammad Bilal, Lobna Eltoukhy, Christoph Loderer & Jesús Fernández-Lucas. (2022) Magnetic Multi-Enzymatic System for Cladribine Manufacturing. International Journal of Molecular Sciences 23:21, pages 13634.
Crossref
Crossref
Katarzyna Rakoczy, Wojciech Szlasa, Natalia Sauer, Jolanta Saczko & Julita Kulbacka. (2022) Molecular relation between biological stress and carcinogenesis. Molecular Biology Reports 49:10, pages 9929-9945.
Crossref
Crossref
Francis R. LeBlanc, Zainul S. Hasanali, August Stuart, Sara Shimko, Kamal Sharma, Violetta V. Leshchenko, Samir Parekh, Haiqing Fu, Ya Zhang, Melvenia M. Martin, Mark Kester, Todd Fox, Jiangang Liao, Thomas P. Loughran, Juanita Evans, Jeffrey J. Pu, Stephen E. Spurgeon, Mirit I. Aladjem & Elliot M. Epner. (2022) Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. Oncotarget 13:1, pages 986-1002.
Crossref
Crossref
Galal H. Elgemeie & Reham A. Mohamed-Ezzat. 2022. New Strategies Targeting Cancer Metabolism. New Strategies Targeting Cancer Metabolism
69
105
.
Shuli Man, Yingying Lu, Lijuan Yin, Xinkuan Cheng & Long Ma. (2021) Potential and promising anticancer drugs from adenosine and its analogs. Drug Discovery Today 26:6, pages 1490-1500.
Crossref
Crossref
Marta Libura, Emilia Bialopiotrowicz, Sebastian Giebel, Agnieszka Wierzbowska, Gail J. Roboz, Beata Piatkowska-Jakubas, Marta Pawelczyk, Patryk Gorniak, Katarzyna Borg, Magdalena Wojtas, Izabella Florek, Karolina Matiakowska, Bozena Jazwiec, Iwona Solarska, Monika Noyszewska-Kania, Karolina Piechna, Magdalena Zawada, Sylwia Czekalska, Zoriana Salamanczuk, Karolina Karabin, Katarzyna Wasilewska, Monika Paluszewska, Elzbieta Urbanowska, Justyna Gajkowska-Kulik, Grazyna Semenczuk, Justyna Rybka, Tomasz Wrobel, Anna Ejduk, Dariusz Kata, Sebastian Grosicki, Tadeusz Robak, Agnieszka Pluta, Agata Kominek, Katarzyna Piwocka, Karolina Pyziak, Agnieszka Sroka-Porada, Anna Wrobel, Agnieszka Przybylowicz, Marzena Wojtaszewska, Krzysztof Lewandowski, Lidia Gil, Agnieszka Piekarska, Wanda Knopinska, Lukasz Bolkun, Krzysztof Warzocha, Kazimierz Kuliczkowski, Tomasz Sacha, Grzegorz Basak, Wieslaw Wiktor Jedrzejczak, Jerzy Holowiecki, Przemysław Juszczynski & Olga Haus. (2021) IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Scientific Reports 11:1.
Crossref
Crossref
Cintia Wanda Rivero, Natalia Soledad García, Jesús Fernández-Lucas, Lorena Betancor, Gustavo Pablo Romanelli & Jorge Abel Trelles. (2021) Green Production of Cladribine by Using Immobilized 2′-Deoxyribosyltransferase from Lactobacillus delbrueckii Stabilized through a Double Covalent/Entrapment Technology. Biomolecules 11:5, pages 657.
Crossref
Crossref
Cintia W. Rivero, Eliana C. De Benedetti, Jorge Sambeth & Jorge A. Trelles. (2020) Biotransformation of cladribine by a nanostabilized extremophilic biocatalyst. Journal of Biotechnology 323, pages 166-173.
Crossref
Crossref
Stephen E. Spurgeon, Kamal Sharma, David F. Claxton, Christopher Ehmann, Jeffrey Pu, Sara Shimko, August Stewart, Nan Subbiah, Gundula Palmbach, Francis LeBlanc, Emile Latour, YiYi Chen, Motomi Mori, Zainul Hasanali & Elliot M. Epner. (2019) Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma. British Journal of Haematology 186:6, pages 845-854.
Crossref
Crossref
Jun Xu, Ting-Ting Lv, Xiao-Fen Zhou, Ying Huang, Dong-Dong Liu & Guo-Lin Yuan. (2018) Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia. Medicine 97:39, pages e12102.
Crossref
Crossref
Mark S. Freedman, Daniel Selchen, Alexandre Prat & Paul S. Giacomini. (2018) Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 45:5, pages 489-503.
Crossref
Crossref
Tapan M Kadia, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Marina Konopleva, Christopher B Benton, Jan Burger, Koji Sasaki, Gautam Borthakur, Courtney D DiNardo, Naveen Pemmaraju, Naval Daver, Alessandra Ferrajoli, Xuemei Wang, Keyur Patel, Jeffrey L Jorgensen, Sa Wang, Susan O'Brien, Sherry Pierce, Carla Tuttle, Zeev Estrov, Srdan Verstovsek, Guillermo Garcia-Manero & Hagop Kantarjian. (2018) Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. The Lancet Haematology 5:9, pages e411-e421.
Crossref
Crossref
Y. Bao, J. Zhao & Z.-Z. Li. (2017) Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study. Clinical and Translational Oncology 20:7, pages 870-880.
Crossref
Crossref
S. Jayashree, K. Nirekshana, Gunjan Guha & Dipita Bhakta-Guha. (2018) Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection. Biomedicine & Pharmacotherapy 102, pages 894-911.
Crossref
Crossref
Soham D. Puvvada, José Guillen-Rodriguez, Abhijeet Kumar, Lora Inclán, Kara Heard, Xavier I. Rivera, Faiz Anwer, Jonathan H. Schatz, Daruka Mahadevan & Daniel O. Persky. (2018) Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. Clinical Lymphoma Myeloma and Leukemia 18:1, pages 58-64.
Crossref
Crossref
Jadd Shelton, Xiao Lu, Joseph A. Hollenbaugh, Jong Hyun Cho, Franck Amblard & Raymond F. Schinazi. (2016) Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chemical Reviews 116:23, pages 14379-14455.
Crossref
Crossref
Alessandro Broccoli, Letizia Gandolfi, Cinzia Pellegrini, Claudio Agostinelli, Lisa Argnani & Pier Luigi Zinzani. (2016) Leukocytoclastic Vasculitis Associated with Hairy Cell Leukemia at Diagnosis: A Case Report and Review of the Literature. Tumori Journal 102:2_suppl, pages S124-S127.
Crossref
Crossref
V. Gupta, B.K. Khaitan, S. Patra & R. Yadav. (2016) Xanthoma disseminatum: improvement in disfiguring facial lesions with cladribine. Journal of the European Academy of Dermatology and Venereology 30:10, pages e43-e44.
Crossref
Crossref
M. Nadeem, O. Mufti, I. Ahsan, R. Naheed & S. M. Faheem. (2016) Treatment of Multiple Sclerosis. Neuroscience and Medicine 07:02, pages 74-82.
Crossref
Crossref
Sibel Hacioglu, Yusuf Bilen, Ali Eser, Serdar Sivgin, Emel Gurkan, Rahsan Yildirim, Ismet Aydogdu, Mehmet Hilmi Dogu, Mehmet Yilmaz, Omur Kayikci, Anil Tombak, Irfan Kuku, Harika Celebi, Meltem Olga Akay, Ramazan Esen, Serdal Korkmaz & Ali Keskin. (2015) Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy. Hematological Oncology 33:4, pages 192-198.
Crossref
Crossref
B C Valdez, J E Brammer, Y Li, D Murray, Y Liu, C Hosing, Y Nieto, R E Champlin & B S Andersson. (2015) Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer Journal 5:10, pages e357-e357.
Crossref
Crossref
Gary S. Wood & Jianqiang Wu. (2015) Methotrexate and Pralatrexate. Dermatologic Clinics 33:4, pages 747-755.
Crossref
Crossref
Zainul S. HasanaliBikramajit Singh SaroyaAugust StuartSara ShimkoJuanita EvansMithun Vinod ShahKamal SharmaVioletta V. LeshchenkoSamir ParekhThomas P. LoughranJr.Jr. & Elliot M. Epner. (2015) Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. Science Translational Medicine 7:293.
Crossref
Crossref
Benigno C. Valdez, Yang Li, David Murray, Jie Ji, Yan Liu, Uday Popat, Richard E. Champlin & Borje S. Andersson. (2015) Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Experimental Hematology 43:6, pages 448-461.e2.
Crossref
Crossref
Stefan Schwarz, Bianka Siewert, René Csuk & Amélia P. Rauter. (2015) New antitumor 6-chloropurine nucleosides inducing apoptosis and G2/M cell cycle arrest. European Journal of Medicinal Chemistry 90, pages 595-602.
Crossref
Crossref
V Maevis, U Mey, G Schmidt-Wolf & I G H Schmidt-Wolf. (2014) Hairy cell leukemia: short review, today’s recommendations and outlook. Blood Cancer Journal 4:2, pages e184-e184.
Crossref
Crossref
R.E. Watson. 2014. Encyclopedia of Toxicology. Encyclopedia of Toxicology
438
443
.
Eileen Magbanua & Ulrich Hahn. 2014. Chemical Biology of Nucleic Acids. Chemical Biology of Nucleic Acids
271
292
.
Marian Jędrych, Ewelina Wawryk-Gawda, Barbara Jodłowska-Jędrych, Patrycja Chylińska-Wrzos & Ludwik Jasiński. (2013) Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovarian surface epithelial cells of cladribine-treated rats. Protoplasma 250:5, pages 1025-1034.
Crossref
Crossref
Patrycja Chylinska-Wrzos, Ewelina Wawryk-Gawda, Marta Lis-Sochocka, Marian Jedrych, Miroslaw Lancut, Kamila Bulak, Joanna Leszcz-Stankiewicz & Barbara Jodlowska-Jedrych. (2013) The intrinsic or the extrinsic pathways of apoptosis in the epidermis after cladribine application?. Journal of Biomedical Science and Engineering 06:03, pages 265-272.
Crossref
Crossref
Vikas Ghai, Kamal Sharma, Kamal K. S. Abbi, Sara Shimko & Elliot M. Epner. 2013. Impact of Genetic Targets on Cancer Therapy. Impact of Genetic Targets on Cancer Therapy
257
266
.
Monika Joshi, Hassan Sheikh, Kamal Abbi, Sarah Long, Kamal Sharma, Mark Tulchinsky & Elliot Epner. (2012) Marginal zone lymphoma: old, new, targeted, and epigenetic therapies. Therapeutic Advances in Hematology 3:5, pages 275-290.
Crossref
Crossref
Karen Schreiber & Per Soelberg Sorensen. (2011) Cladribine in the treatment of multiple sclerosis. Clinical Investigation 1:2, pages 317-326.
Crossref
Crossref
Mitchell R Smith. (2011) Should there be a standard therapy for mantle cell lymphoma?. Future Oncology 7:2, pages 227-237.
Crossref
Crossref
Francesca BagnatoIstvan Pirko. (2011) Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis. What Role for Cladribine?. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6456.
Crossref
Crossref
Thomas P. Leist & Robert Weissert. (2011) Cladribine. Clinical Neuropharmacology 34:1, pages 28-35.
Crossref
Crossref
Steven Carsons. 2012. Sjögren’s Syndrome. Sjögren’s Syndrome
571
578
.
Darren S. Sigal, Heather J. Miller, Ethan D. Schram & Alan Saven. (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 116:16, pages 2884-2896.
Crossref
Crossref
S. Schmidt. (2010) Cladribin-Tabletten bei schubförmiger Multipler SkleroseOral cladribine for relapsing-remitting multiple sclerosis. Der Nervenarzt 81:10, pages 1231-1241.
Crossref
Crossref